Updates are available Correction dated 2026-04-27
Click to view Correction: https://doi.org/10.1007/s12015-026-11123-7
-
Authors
Peng, Tingting Jr
Lin, Huijuan
Zeng, Xiaoli
Xie, Yunlan
Luo, Jie
Zhang, Lingjie
Huang, Shiya
Ye, Zhiyi
Guo, Xiaolin
Le, Wen
Zhang, Mingtong
Li, Wenhui
Peng, Tingting Sr
Liu, Liru
Han, Mingshan
Gao, Ting
Tang, Hongmei
Zhang, Jing
He, Lu
Xu, Kaishou
-
Funding
Funding for this research was provided by:
Natural Science Foundation of Guangdong Province (2024A1515012920)
Natural Science Foundation of Guangdong Province (2025A1515010379)
Guangdong Special Support Program for Young Top-notch Talents in Health and Health Research (0820250251)
Major Innovation Technology Construction Project of Synergistic Chinese Medicine and Western Medicine of Guangzhou (2023-2318)
National Natural Science Foundation of China (82472598)
Guangzhou Municipal Science and Technology Project (2024A03J01274)
Guangzhou Clinical Characteristic Technology Program (2023C-TS59)
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 27 January 2026
First Online: 23 February 2026
Change Date: 13 April 2026
Change Type: Update
Change Details: The original online version of this article was revised: The original online version of this article was revised:In the published article, Figure 2K appeared incorrectly due to labeling error in the Western Blot. This correction does not alter the scientific conclusions of the paper. The characterization of hUCMSC-Exos (positive for CD9/CD63, negative for Calnexin) remains valid. The authors sincerely apologize for any inconvenience this may cause to the editors and readers.
Change Date: 27 April 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12015-026-11123-7
Declarations
:
: All procedures were approved by the Laboratory Animal Committee of Guangzhou Women and Children’s Medical Center. (1) Title of the approved project: Preclinical efficacy study of intravenously transplanted mesenchymal stem cell-derived exosomes for moderate-to-severe cerebral palsy; (2) Name of the institutional approval committee: Laboratory Animal Committee of Guangzhou Women and Children’s Medical Center; (3) Approval number: RSDW-2024-01077; (4) Date of approval: 5th June 2024. Human material has been performed in accordance with the Declaration of Helsinki. The hUCMSC-Exos used in this study were all supplied by Guangdong Xiangxue Stem Cell Regenerative Medicine Technology Co., Ltd, and approved by the National Institutes for Food and Drug Control (Report number: SH202207163, Date of approval: 4th November 2022). Human umbilical cord tissue was sourced from healthy volunteer pregnant women, all of whom signed an informed consent form prior to delivery.
: Not applicable.
: Not applicable.
: The authors declare no competing interests.
